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OBJECTIVE — Participants in the Diabetes Prevention Program (DPP) randomized to inten-
sive lifestyle modiﬁcation (ILS) or metformin had a signiﬁcantly reduced incidence of diabetes
compared with those randomized to placebo, yet most were still at risk because they had
pre-diabetes. We explored the effect of baseline characteristics, weight change, ILS, and met-
formin on regression from pre-diabetes to the lowest-risk state of normal glucose regulation
(NGR) deﬁned by American Diabetes Association criteria.
RESEARCHDESIGNANDMETHODS — TheDPPwasaprospectiverandomizedtrial.
Cox proportional hazards modeling was used to identify predictors of regression from pre-
diabetes to NGR over 3 years of follow-up.
RESULTS — Lower baseline fasting (hazard ratio 1.52, P  0.01) and 2-h (1.24, P  0.01)
glucose predicted regression to NGR, as did younger age (1.07, P  0.01) and greater insulin
secretion(1.09,P0.04).ILS(2.05,P0.01)andweightloss(1.34,P0.01)hadsigniﬁcant
and independent effects on regression. A nonsigniﬁcant trend for regression was also observed
for metformin (1.25, P  0.06), male sex (1.17, P  0.08), and insulin sensitivity (1.07, P 
0.09).Inthoseenteringthestudywithbothimpairedfastingglucose(IFG)andimpairedglucose
tolerance (IGT), male sex and insulin sensitivity predicted regression to isolated IFG, whereas
ILS, metformin, female sex, and greater insulin secretion predicted regression to isolated IGT.
CONCLUSIONS — Insulin secretion, and other biologic processes retained with younger
age, are key in restoring NGR in people with pre-diabetes. However, NGR may also be attained
through weight loss and additional aspects of ILS.
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T
he prevalence of type 2 diabetes in-
creased61%between1990and2001
(1), and by 2005 it affected nearly 21
millionAmericans(www.cdc.gov/Diabetes/
pubs/estimates05.htm). This trend shows
no sign of abating, considering that there
are currently an estimated 54 million
Americans with pre-diabetes (i.e., im-
paired fasting glucose [IFG] and/or im-
paired glucose tolerance [IGT]), up to
70% of whom may develop diabetes in
their lifetime (2–4). Consequently, a
number of clinical trials (2,4–9) have ex-
amined the feasibility and efﬁcacy of life-
style and/or drug therapy at preventing
diabetes in people with pre-diabetes. To-
gether, these studies have demonstrated
reductions between 25 and 67% in the
incidence of diabetes over 2.5- to 6-year
intervention periods, with most partici-
pants remaining in a pre-diabetic state.
Less often discussed were the 20–50% of
participants who not only did not
progress but, in fact, returned to normal
glucose regulation (NGR) (2,6–8). One
could make the case that true risk reduc-
tion is in restoring NGR rather than in
maintenance of pre-diabetes.
Whereas risk factors for diabetes are
well established (3), far less is known
about factors associated with reversal of
the process. There are a large number of
possible candidates, including a variety
of genes, environmental exposures, and
aspects of behavior, including diet, phys-
ical activity, and stress responses. Data
from the Diabetes Prevention Program
(DPP)offeredauniqueopportunitytoex-
plore some of these possible mediators.
Thus, we aimed to examine the effect of
basal biologic factors, weight change, and
prevention strategies (intensive lifestyle
modiﬁcation [ILS] or metformin) on the
incidence of regression from pre-diabetes
to NGR.
RESEARCH DESIGN AND
METHODS— The DPP was a ran-
domized clinical trial performed at 27
centers involving 3,234 subjects who
were at high risk for diabetes. The de-
tailed methods have been reported (10),
and the protocol is available at http://
www.bsc.gwu.edu/dpp. Institutional re-
view boards at each center approved the
protocol,andallparticipantsgavewritten
informed consent prior to participation.
Eligibility criteria included being age
25 years, having a BMI 24 kg/m
2
(22 kg/m
2 in Asian Americans), having
a fasting plasma glucose concentration of
5.3–6.9 mmol/l (6.9 mmol/l in the
American Indian clinics), and attaining a
2-h glucose of 7.8–11.0 mmol/l during a
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participants had IGT at baseline. Subjects
were excluded if they were taking medi-
cations known to alter glucose tolerance
or had signiﬁcant illness.
Interventions
Eligible participants were randomly as-
signed to one of three interventions: 1)
ILS, 2) 850 mg metformin twice daily and
standardlifestylerecommendations,or3)
placebo twice daily and standard lifestyle
recommendations. The goal for partici-
pants assigned to ILS was to achieve and
maintainaweightreductionofatleast7%
of their initial body weight through a
healthy low-calorie, low-fat diet and




Self-reported levels of leisure physical ac-
tivitywereassessedsemiannuallywiththe
Modiﬁable Activity Questionnaire (10).
The physical activity level was calculated
as the product of the duration and fre-
quency of each activity (in hours per
week)weightedbyanestimateofthemet-
abolic equivalent (MET) of that activity
and summed for all activities performed
with the result expressed as the average
MET hours per week for the previous
year. Usual daily caloric intake during the
previous year, including calories from fat,
carbohydrate, protein, and other nutri-
ents,wasassessedatbaselineandat1year
with the use of a modiﬁed version of the
Block food frequency questionnaire
(10). Weight was measured using a
standardized calibrated scale, and
blood pressure was measured using a
manual sphygmomanometer.
Venous blood was obtained and
processed at each clinical site using a
standardized manual of operations. Par-
ticipants randomized to metformin did
not take the medication the morning of
blood testing. Serum and plasma samples
were stored at – 20°C for several days and
then shipped in batches on dry ice to a
single central laboratory. Measurement
methods for glucose, insulin, triglycer-
ides,andHDLcholesterolhavebeenpub-
lished (11). Measures of insulin secretion
(corrected insulin response [CIR] 
[100  30 min insulin]/[30 min glu-
cose  {30 min glucose  70}]) and in-
sulin sensitivity (1/fasting insulin) were
calculated using validated indices (12).
Outcome measures and statistical
analyses
Of 3,234 participants in the DPP, 2,528
had a baseline fasting glucose concentra-
tion 5.6 mmol/l (and 7.0 mmol/l)
and, thus, according to American Diabe-
tes Association (ADA) criteria were con-
sidered to have IFG in addition to IGT
(13). The primary outcome measure was
regression from combined IFG/IGT to
NGR (fasting glucose 5.6 mmol/l and
2-h glucose 7.8 mmol/l), with second-
ary outcome measures such as regression
fromIFG/IGTtoisolatedIFG(fastingglu-
cose 5.6–6.9 mmol/l and 2-h glucose
7.8mmol/l)orisolatedIGT(fastingglu-
cose 5.6 mmol/l and 2-h glucose 7.8–
11.1 mmol/l), again using ADA criteria
(13). Analyses also examined predictors
for regression from IFG/IGT to NGR, iso-
lated IFG, or isolated IGT within each
treatment group. Another set of models
was constructed analyzing regression in
the DPP cohort (those who had IGT with
a fasting plasma glucose concentration
5.3 mmol/l [and 7.0 mmol/l] [n 
3,143] and regressed to NGR [n  468],
isolated IFG [n  1,150], or isolated IGT
[n  279]). Quantitative characteristics
are presented as the median (25th and
75th percentiles) and qualitative charac-
teristics as n (%). The effect of baseline
characteristics, as well as the effect of
weightchange,ILS,andmetforminversus
placebo, on the incidence of regression
was estimated using Cox proportional
hazards modeling. In circumstances
where variables had signiﬁcant colinear-
ity (e.g., weight and BMI), only one vari-
able was included. Cox proportional
hazards models included only partici-
pants with IFG/IGT and modeled time to
ﬁrst incidence of regression to NGR, iso-
latedIFG,orisolatedIGTusingyearlyvis-
its. Those who had progressed to
diabetes, had missing data, or, depending
on the outcome measure of the model,
regressed to NGR, isolated IFG, or iso-
latedIGTwerecensoredfromsubsequent
analyses (Fig. 1). Hazard ratios (HRs) for
continuous variables are presented per
SD for each variable of interest (except
age, which is for an increase of 5 years).
An HR 1 indicates greater risk for re-
gression (i.e., favors regression), whereas
the opposite is true for HR 1 (i.e., im-
pedes regression). P values for individual
covariateswerecalculatedusingtheWald
Figure 1—Flowchart for primary data analysis illustrating handling of the data from years 1 to
3. IFG, fasting glucose  5.6–6.9 mmol/l; IGT, 2-h glucose  7.8–11.1 mmol/l; NGR, fasting
glucose 5.6 mmol/l; and 2-h glucose 7.8 mmol/l. Data “not included” were censored from
subsequentanalysesduetoregressiontoNGR(inyearprior),isolatedIFGorIGT,progressionto
diabetes, or missing data.
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overall model. Stratiﬁed analyses were
conductedﬁrstbytreatmentgroupwitha
test for heterogeneity, checking whether
the effect of a covariate is the same across
treatment groups. Signiﬁcance was set at
P  0.05. All analyses were conducted




Baseline characteristics for the entire DPP
cohort have been previously published
(11).BaselinecharacteristicsfortheADA-
deﬁned IFG/IGT cohort (fasting glucose
5.6–6.9 mmol/l and 2-h glucose 7.8–
11.1mmol/lasopposedtofastingglucose
5.3–6.9 mmol/l and 2-h glucose 7.8–
11.1mmol/lfortheentireDPPcohort)are
summarized in Table 1 by treatment
group.Nosigniﬁcantdifferenceswereob-
served between the randomized groups
by treatment assignment for the variables
shown, except for diastolic blood pres-
sure and HDL cholesterol that were bor-
derline signiﬁcant. Further, there was no
signiﬁcant difference between the treat-
ment groups in baseline characteristics
(except HDL cholesterol) using a fasting
glucose cut point of 5.3 mmol/l (data not
shown).
Predictors for regression to NGR
Results from the ﬁnal multivariate model,
shown in Table 2, included treatment
group,age,sex,ethnicity,baselineweight
andchangeinweight,baselinefastingand
2-h plasma glucose concentrations, and
indices of the -cell’s insulin response
andtissueinsulinsensitivity,aseachwere
signiﬁcantly and independently predic-
tive of regression to NGR in a univariate
analysis. As expected, lower baseline fast-
ing and 2-h glucose predicted regression
to NGR, as did younger age and a greater
insulin secretion to the oral glucose load.
ILSandgreaterweightlosshadsigniﬁcant
and independent effects on regression. A
nonsigniﬁcant trend for metformin, male
sex, and greater insulin sensitivity on in-
cidence of regression was also observed.
Thecumulativeincidenceofregressionto
NGR in each treatment group is shown in
Fig.2.Whenthemodelwasrunusingthe
entire DPP cohort (fasting glucose 5.3–
6.9 vs. 5.6–6.9 mmol/l), the results were
similar (data not shown).
When examining the data by treat-
ment group, Caucasian self-reported
ethnicity was signiﬁcantly associated
with less likelihood of regression (HR
0.68, P  0.02), but only in the met-
formin group, and therefore is of uncer-
tain signiﬁcance. Contribution from a
positive family history of diabetes, lip-
ids, blood pressure, use of lipid- and/or
blood pressure–lowering medications,
selective serotonin reuptake inhibitors,
or hormone replacement therapy, di-
etary calories from fat, and MET/h per
week of physical activity were also ex-
plored and found to not be signiﬁcantly
related to regression to NGR (data not
shown).
Predictors of regression to isolated
IFG
Higher fasting and lower 2-h glucose, as
well as male sex and greater insulin sen-
sitivity,wereassociatedwithregressionto
isolatedIFG,asdeﬁnedbyADA(Table2).
The relationship between ILS and regres-
siontoIFGwasofborderlinesigniﬁcance.
When the entire DPP cohort was ana-
lyzed, higher fasting glucose (HR 1.14,
P  0.01), lower 2-h glucose (1.43, P 
0.01), male sex (1.35, P  0.01), and
greaterinsulinsensitivity(1.08,P0.02)
remained similarly predictive. The power
gained by using the entire cohort in-
creasedtheabilitytodetectaneffectofILS
Table 1—Baseline characteristics of participants with both IFG and IGT, deﬁned by the ADA
ILS Metformin Placebo
n 850 832 846
Age (years) 50 (42–59) 51 (44–57) 50 (44–58)
Female 555 (65.3) 528 (63.5) 559 (66.1)
Race/ethnic group
White 456 (53.6) 474 (57.0) 458 (54.1)
African American 164 (19.3) 183 (22.0) 184 (21.7)
Hispanic 143 (16.8) 125 (15.0) 132 (15.6)
American Indian 36 (4.2) 21 (2.5) 31 (3.7)
Asian American 51 (6.0) 29 (3.5) 41 (4.8)
Systolic blood pressure (mmHg) 122 (113–133) 123 (113–134) 122 (114–132)
Diastolic blood pressure (mmHg) 79 (73–85) 79 (72–85) 78 (71–84)
Waist circumference (cm) 104 (95–115) 105 (96–114) 105 (96–115)
BMI (kg/m
2) 33 (29–37) 33 (29–37) 33 (29–38)
Activity (MET/h per week)
Leisure 9.5 (3.7–20) 10 (3.9–21) 9.8 (4.1–21)
Recreational 62 (36–91) 63 (38–91) 62 (39–90)
Caloric intake (kcal) 1,881 (1,463–2,573) 1,902 (1,472–2,568) 1,874 (1,443–2,474)
Fasting plasma glucose (mmol/l) 5.9 (5.7–6.3) 5.9 (5.7–6.3) 5.9 (5.7–6.3)
2-h plasma glucose (mmol/l) 9.1 (8.3–9.9) 9.2 (8.4–10.0) 9.1 (8.3–9.9)
Triglycerides (mmol/l) 1.6 (1.1–2.3) 1.6 (1.1–2.2) 1.7 (1.2–2.4)
HDL cholesterol (mmol/l) 1.1 (1.0–1.3) 1.1 (1.0–1.3) 1.1 (0.9–1.3)
Insulin secretion 0.52 (0.35–0.74) 0.51 (0.34–0.74) 0.53 (0.34–0.78)
Insulin sensitivity 0.04 (0.03–0.06) 0.04 (0.03–0.06) 0.04 (0.03–0.06)
Data are n (%) for categorical variables and median (25th–75th percentile) for continuous variables. Twenty Paciﬁc Islanders were included in the Asian American
group. Insulin secretion was estimated using the CIR (100  30 min insulin/30 min glucose  {30 min glucose 70}). Insulin sensitivity was estimated using
1/fasting insulin.
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for younger age (1.03, P  0.07) to posi-
tivelyinﬂuenceregressiontoisolatedIFG.
Within–treatment group comparisons
noted a stronger effect of low 2-h glucose
on regression in placebo (HR 1.64) and
metformin (1.61) groups than in the ILS
group (1.25) (test for interaction, P 
0.03).
Predictors of regression to isolated
IGT
Lower fasting and higher 2-h glucose,
female sex, a greater insulin secretion,
as well as both ILS and metformin were
associated with regression to isolated
IGTintheADA-deﬁnedIFG/IGTcohort
(Table 2). Greater weight loss was mar-
ginallyassociatedwithregressiontoiso-
lated IGT. When the same analysis was
performed in the entire DPP cohort,
lower fasting glucose (HR 2.36, P 
0.01), higher 2-h glucose (1.15, P 
0.02), female sex (1.54, P  0.01), ILS
(1.46, P  0.02), and metformin (1.89,
P  0.01) remained similarly predic-
tive. In contrast, insulin response was
no longer signiﬁcantly related (1.01,
P  0.86), but younger age was (1.06,
P  0.05). In addition, marginal associ-
ations emerged for lower baseline
weight (1.13, P  0.09) and greater
weightloss(1.17,P  0.07)inﬂuencing
regression to isolated IGT. No differ-
ence in predictors for regression within
treatment groups was observed.
CONCLUSIONS — As the epidemic
of diabetes continues to worsen, develop-
ing and implementing preventive strate-
gies has become critical. A number of
clinical trials (2,4–9) have demonstrated
the effectiveness of lifestyle and/or drug
therapy at preventing diabetes in people
with pre-diabetes, but none have exam-
ined the effectiveness of an intervention
on returning those with pre-diabetes to
NGR.Toexpandtheparadigmofdiabetes
prevention, the aim of the current study
was to examine the effect of basal biologic
factors, weight change, and prevention
strategies (ILS or metformin) on the inci-
dence of regression from pre-diabetes to
NGR. The major ﬁndings from this anal-
ysis were that 1) insulin secretion, and
other biologic processes that are retained
with younger age, are key in the restora-
tion of NGR in people with pre-diabetes;
however, 2) NGR may also be attained
through weight loss and additional as-
pects of ILS, such as healthy eating and
exercise.
ILS and metformin both have been
shown to be effective strategies for diabe-
tes prevention, but in the DPP only ILS
restored NGR signiﬁcantly more fre-
quently than did placebo (2). Different
impact of ILS versus metformin on pa-
rametersofinsulinsensitivityorsecretion
did not explain these results. This obser-
vation lends support for the notion that
aspects of ILS beyond insulin sensitiza-
tion per se are key in truly reducing dia-
betes risk.
Weight loss appears to be the most
important component of ILS predicting
regression, with every 1 kg lost associated
with a 16% reduction in diabetes risk
(14). Weight loss strategies inclusive of
exercise preferentially mobilize fat from
the visceral depot, inducing more favor-
able metabolic results than would fat mo-
bilized from the subcutaneous depot
(15). Interestingly, however, ILS, inde-
pendent of weight loss, also predicted re-
gression to NGR in our study. This
ﬁndingimpliesarolefortheotheraspects
of ILS, such as healthy eating or exercise,
in restoring NGR. Indeed, healthy eating
(16)andexercise(17)withoutweightloss
have been previously and independently
demonstrated as positive effectors on the
metabolic milieu; however, we found no
predictive effect toward regression for ei-
therinthecurrentanalysis.Thecombina-
tion of healthy eating with exercise or
other pleiotropic effects of exercise may
explain these ﬁndings but were not as-
sessed in DPP participants.
Table2—PredictorsofregressiontoNGR,isolatedIFG,orisolatedIGTusingADAcriteriain
a multivariate model
HR (95% CI) P
Regression to NGR
ILS versus placebo 2.05 (1.66–2.53) 0.0001
Metformin versus placebo 1.25 (0.99–1.58) 0.0601
Younger age 1.07 (1.02–1.11) 0.0031
Male versus female sex 1.17 (0.98–1.40) 0.0784
Caucasian versus non-Caucasian 1.00 (0.84–1.19) 0.9986
Lower fasting plasma glucose 1.52 (1.36–1.68) 0.0001
Lower 2-h plasma glucose 1.24 (1.13–1.35) 0.0001
Greater insulin sensitivity (l/fasting insulin) 1.07 (0.99–1.16) 0.0934
Greater insulin secretion (CIR) 1.09 (1.01–1.17) 0.0353
Higher baseline weight 1.01 (0.92–1.11) 0.8229
Greater weight loss 1.34 (1.21–1.49) 0.0001
Regression to isolated IFG
ILS versus placebo 1.20 (0.99–1.46) 0.0576
Metformin versus placebo 0.98 (0.81–1.19) 0.8560
Younger age 1.03 (0.99–1.07) 0.1590
Male versus female sex 1.27 (1.08–1.50) 0.0037
Caucasian versus non-Caucasian 1.07 (0.91–1.26) 0.4088
Higher fasting plasma glucose 1.29 (1.19–1.40) 0.0001
Lower 2-h plasma glucose 1.48 (1.36–1.61) 0.0001
Greater insulin sensitivity (l/fasting insulin) 1.09 (1.00–1.18) 0.0441
Greater insulin secretion (CIR) 1.05 (0.96–1.15) 0.2591
Higher baseline weight 1.03 (0.95–1.13) 0.4467
Greater weight loss 0.98 (0.89–1.07) 0.5962
Regression to isolated IGT
ILS versus placebo 1.30 (1.01–1.67) 0.0397
Metformin versus placebo 1.50 (1.18–1.91) 0.0009
Younger age 1.01 (0.96–1.06) 0.7587
Female versus male sex 1.58 (1.25–1.99) 0.0001
Caucasian versus non-Caucasian 1.13 (0.93–1.38) 0.2259
Lower fasting plasma glucose 1.67 (1.47–1.89) 0.0001
Higher 2-h plasma glucose 1.19 (1.08–1.31) 0.0004
Greater insulin sensitivity (l/fasting insulin) 1.01 (0.91–1.12) 0.8854
Greater insulin secretion (CIR) 1.11 (1.01–1.23) 0.0257
Higher baseline weight 0.93 (0.83–1.03) 0.1733
Greater weight loss 1.13 (1.00–1.28) 0.0558
HRs for continuous variables are per 1 SD (or per 5 years for age).
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predictors of regression to NGR are not
modiﬁable. For example, younger age
was associated with regression to NGR in
the current study. This was seen despite
the previous ﬁnding that older DPP par-
ticipants had greater success meeting ILS
goals and with it the beneﬁcial effect of
lower diabetes incidence (18). What age-
related processes may be responsible is
speculative.Considerablecontroversyex-
istsastowhetheragebyitself(19)(versus
age-related body composition change
[20]) leads to the deterioration of insulin
action and/or secretion.
Greater insulin secretion also pre-
dicted regression to NGR and may reﬂect
the critical link between ILS, weight loss,
and age in restoring and maintaining
NGR. Weight loss and younger age either
resultedin,orwereassociatedwith,lower
baseline 2-h glucose levels in the DPP,
likelyreﬂectingthemorerobust-cellre-
sponsivenessinthesegroups.Insulinsen-
sitivity and secretion are integrally
related, and the deterioration of each is
felt to be requisite in the development of
type 2 diabetes (21). Nevertheless, longi-
tudinal data (22) clearly demonstrate the
failureofthe-cellastheseminaleventin
this process. Therefore, one could sur-
mise that the maintenance of insulin se-
cretion is vital, as insulin sensitivity may
be modiﬁed more readily than insulin se-
cretion by ILS, weight loss, and/or age-
related body composition changes.
All participants in the DPP had ele-
vated 2-h and high-normal fasting glu-
cose concentrations. As the combination
of increasing fasting and 2-h glucose lev-
els confers greater risk for diabetes than
either in isolation (3), there is reason to
believe that regression from IFG/IGT to
isolated IFG or IGT may also decrease di-
abetes risk. Other than the expected pre-
dictive effects of glucose concentration
itself(highfastingandlow2-hglucosefor
IFG and the converse for IGT) and inter-
vention effects on glucose concentration
(ILS on fasting and 2-h glucose, met-
formin on fasting), we observed distinct
predictors for reversion to isolated IFG
and isolated IGT, likely reﬂecting their
different pathophysiology (23). Consis-
tent with some, but not all, cross-
sectional studies, those with isolated IFG
were more likely to be insulin sensitive
and male, whereas those with isolated
IGT were more likely to have retained in-
sulin secretion and be female (24,25).
Several limitations of the current
study are worth noting. First, the primary
analyses were conducted using the ADA
deﬁnitionofIFG,whichreducedthesam-
plesizeandpowertoﬁnddifferences.Ad-
ditionally, the considerable amount of
missing data exacerbated this issue. Nev-
ertheless, when the entire cohort was
analyzed, the results were largely un-
changed.Second,byvirtueofouranalysis
plan, the fate of those who may have
changed glucose tolerance status more
than once, spontaneously regressed, or
were incorrectly classiﬁed due to the in-
accuracyoftheoralglucosetolerancetest,
was not captured. Finally, analyses were
post hoc and exploratory with the inten-
tion of generating hypotheses and discus-
sion on this topic. Prospective studies are
needed to conﬁrm the current ﬁndings.
In conclusion, true diabetes preven-
tion likely resides in the restoration of
NGR rather than in the maintenance of a
high-risk state, such as pre-diabetes.
SomefactorsgoverningthereturntoNGR
are modiﬁable, and others are not. For
example, age-related changes, particu-
larly when leading to diminished insulin
secretion, may permanently impede res-
toration of NGR. In other circumstances,
however, NGR may be attained through
weight loss and the combined aspects of
ILS. Establishing healthy habits early in
life, before age-related changes occur, is
most likely the best strategy for diabetes
prevention.
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